Sarcoma & GIST
News
Targeting gene rearrangements shows promise in early study
Key clinical point: Entrectinib showed antitumor activity including intracranial responses.
News
Older patients with soft tissue sarcoma may receive greater benefit from RT
Key clinical point: For many subtypes of soft tissue sarcoma (STS), overall survival (OS) was significantly greater in older patients who received...
News
Feds advance cancer moonshot with expert panel, outline of goals
Possible opportunities include vaccine development, early-detection technology, single-cell genomic analysis, immunotherapy, a focus on pediatric...
Conference Coverage
Better sarcoma outcomes at high-volume centers
Key clinical point: Surgical volume, a surrogate for experience, has been shown to have a direct correlation with patient outcomes for cancers of...
Conference Coverage
CT of chest, extremity effective for sarcoma follow-up
Key clinical point: Lower-cost CT scans of the extremity and chest appear to be effective for surveillance of patients following resection of soft...
News
Bone sarcomas are not just for kids
Key clinical point: Sarcomas of bone have their peak incidence in children and adolescents, but are also seen in adults. Major finding: Findings...
Conference Coverage
Trabectedin found to benefit patients with uterine leiomyosarcoma
Among patients with uterine leiomyosarcoma who underwent prior chemotherapy, treatment with trabectedin resulted in superior disease control, with...
News
PFS a surrogate for overall survival in soft tissue sarcoma trials
Key clinical point: In randomized trials of advanced soft tissue sarcoma, intermediate endpoints of progression-free survival and response rate...
News
HDAC inhibition may reverse anthracycline resistance in patients with sarcoma
Key clinical point: Despite prior exposure to multiple regimens, clinical benefit was observed in several patients with advanced solid tumors,...
News
FDA approves eribulin for advanced liposarcoma
Median overall survival was 15.6 vs. 8.4 months and median progression-free survival was 2.9 vs. 1.7 months in patients with liposarcoma treated...
News
IDH1 mutant inhibitor targets gliomas, chondrosarcomas
Key clinical point: AG-120 is a first-in-class inhibitor of IDH1 mutations that may drive oncogenesis. Major finding: 10 of 20 patients with...